Excel Life Sciences (ELS) is a U.S.-based, India focused, provider of comprehensive clinical trial management services, focusing on site performance, patient enrollment and on-time study completion.

ELS’ success is built around passionate and experienced individuals working alongside our clients to accelerate clinical research and deliver new drugs and medical devices to the markets, while maintaining the highest standards of quality. As a trial management organization, we are also committed to improving and expanding the clinical research enterprise in India, evident through our presentations at conferences, peer-reviewed publications, and continuing relationships with academic institutions.

ELS in brief:

• ELS is a U.S.-based Delaware Corporation with a fully owned Indian subsidiary focused exclusively on clinical research
• ELS has 25 operational locations across India and three U.S. offices in Boston, Chicago, Raleigh/Durham
• The ELS clinical operations team is one of the most experienced and respected in India with over 125 years of collective experience in conducting more than 350 global and domestic clinical trials at hundreds of sites and with thousands of patients
• ELS has trained over 1,500 clinical research personnel in India
Design  Building advice Development of scripts Accommodation of clauses
• The ELS executive team has spoken at an estimated 150 conferences and has published more than 50 articles or chapters in clinical research industry trade journals, magazines and books

ELS’ senior management team members are drawn from the leading companies in the clinical trials industry and the broader business world, including: Sandoz, Upjohn, Pfizer, Thomson Corporation, CenterWatch, Quintiles, D. Anderson & Company, Microsoft, American Express and Marriott International.

At ELS, our extensive domain knowledge helps us understand the expectations and needs of biopharmaceutical and device companies in the U.S. and Europe. Our India operations team and our strategic partners in Eastern Europe and South America ensure high quality, cost effective and efficient execution of global drug and device development programs.